[Experimental study on in vivo hematopoietic regulation of IL-6 gene-transfected tumor vaccine].
In the present study, we investigated the effects on hematopoiesis of inactivated vaccines prepared from mouse erythroid leukemia cells (FBL-3) transfected with IL-6 gene. After treatment with IL-6 gene-transfected FBL-3 cells, the platelet count in mice started to increase at day 4, reached its maximum at day 10 and lasted for 25 days. The neutrophil count also increased significantly, but WBC count remained unchanged. The CFU-GM and CFU-MK were elevated to some extent in bone marrow and spleen. These results indicated that in addition to augmentation of antitumor immunity, IL-6 gene-transfected tumor vaccine could promote hematopoietic functions in bone marrow and spleen, and elevate platelet and neutrophil counts in peripheral blood. This approach to gene therapy may be applicable in leukemia treatment, especially for thrombocytopenia related to leukemia or chemotherapy.
Ge
L
L
Department of Immunology, Second Military Medical University, Shanghai.
Cao
X
X
Cai
R
R
D000818:Animals; D002452:Cell Count; D003114:Colony-Forming Units Assay; D005796:Genes; D015316:Genetic Therapy; D006412:Hematopoietic Stem Cells / Q000473:pathology*; D015850:Interleukin-6 / Q000235:genetics*; D007942:Leukemia, Experimental / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D010976:Platelet Count; D014162:Transfection; D014407:Tumor Cells, Cultured; D015164:Vaccines, Inactivated
D015850:Interleukin-6; D015164:Vaccines, Inactivated